Early trial of new drug shows promise for patients with triple-negative breast cancer

In patients with metastatic triple-negative breast cancer, infusion of pembrolizumab produced durable responses in almost one out of five patients. One of the 27 patients had a complete response and four had a partial response. Seven more patients had stable disease. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *